Cervarix – Page 4 – Oral Cancer News

Boys need the cervical cancer jab, too

Source: www.telegraph.co.uk Author: Max Pemberton Few politicians will ever admit they are wrong, so I salute health ministers who have finally capitulated to medical opinion and last month announced a U-turn on the cervical cancer vaccine that is given to 12- and 13-year-old girls. Until now, Cervarix, which protects against two strains of the human papilloma virus (HPV) that are a factor in at least 70 per cent of diagnoses, has been the NHS vaccine of choice. However, another vaccine, Gardasil, also protects against a further two strains of HPV which cause genital warts, the most common sexually-transmitted infection, requiring costly and unpleasant treatment. As doctors have been arguing for some time, this has important public health implications. The current cost to the NHS of treating the 100,000 new cases of genital warts in England each year is £23 million. In several countries, including Australia, where Gardasil has been used in nationwide vaccination programmes, a 75 per cent decrease in the number of new cases of genital warts in the past three years has been reported. Critics of NHS policy complained that Cervarix was chosen over Gardasil not on the basis of clinical efficacy but because its manufacturers offered it at a discounted price, making it the most cost-effective. Indeed, many doctors have admitted in the medical press that they have bought Gardasil for their daughters privately, while they had to give their patients Cervarix. But ministers have seen sense as now Gardasil will be available on the NHS. But the [...]

Oral Cancer Foundation News Team - A2011-12-05T09:29:57-07:00December, 2011|Oral Cancer News|

HPV vaccine myths put health, lives at risk, say health leaders: Airing the facts

Source: TheNationsHealth.org Vaccination rates for human papillomavirus are lagging for teens, and a complicated web of confusion and misinformation may be to blame, according to public health leaders. Several strains of HPV can cause cervical cancer, and two vaccines, Gardasil and Cervarix, have been shown conclusively to defend against those strains. The Food and Drug Administration recommended in 2006 that girls receive the vaccine before they become sexually active so that they are protected at the outset. In 2009, FDA approved the use of the vaccine for boys as well. According to the Centers for Disease Control and Prevention, about 6 million people in the U.S. become infected with HPV each year and each year about 12,000 women are diagnosed with cervical cancer, leading to about 4,000 deaths. Studies have shown the vaccine to be overwhelmingly safe, CDC said. As of June 2011, about 35 million doses of Gardasil had been distributed in the United States. CDC’s adverse event tracking mechanisms reported about 18,000 adverse events, 92 percent of which were nonserious events, such as fainting, swelling at the injection site and headache. Sixty-eight deaths were reported, but there is “no unusual pattern or clustering to the deaths that would suggest that they were caused by the vaccine, and some reports indicated a cause of death unrelated to vaccination,” CDC said. And yet, fed perhaps by misinformation or squeamishness about the idea of their children becoming sexually active, some parents are opting not to vaccinate, and the vaccination rates are [...]

Oral Cancer Foundation News Team - A2011-12-01T12:41:51-07:00December, 2011|Oral Cancer News|

Use and Acceptance of HPV Vaccine Still a Work in Progress

Source: National Cancer Institute A bellwether moment in the history of cancer prevention came in 2006 when the Food and Drug Administration (FDA) approved the first vaccine to prevent cervical cancer. The vaccine, Gardasil, protects against the two primary cancer-causing, or oncogenic, types of the human papillomavirus (HPV)—HPV-16 and HPV-18. These types are responsible for more than 70 percent of cervical cancer cases worldwide. In 2009, the FDA approved a second HPV vaccine, Cervarix, which also targets HPV-16 and HPV-18. Gardasil and Cervarix, vaccines that protect against the two primary cancer-causing types of the human papillomavirus (HPV), entail a three-shot regimen, with each dose delivered several months apart. But what has transpired since these two vaccines received regulatory blessing in the United States has reaffirmed something that cancer and public health researchers have appreciated for some time: The translation of basic research to the clinic doesn’t end with FDA approval of a new drug or treatment. In many respects, FDA approval is just a beginning. In March 2007, the CDC’s Advisory Committee on Immunization Practices (ACIP) gave its strongest recommendation for HPV vaccination for females ages 9 to 26, which is the FDA-approved indication for Gardasil. Cervarix is approved for females ages 10 to 25. Both vaccines entail a three-shot regimen, with the doses delivered several months apart. According to the most recent data, only 44 percent of adolescent girls 13 to 17 years of age have received at least one dose of the vaccine. Completion rates for the three-shot [...]

Oral Cancer Foundation News Team - A2011-11-30T10:47:00-07:00November, 2011|Oral Cancer News|

Trial Confirms Efficacy of HPV Vaccine, Shows Cross-Protection

Source: National Cancer Institute End-of-trial results from a trial testing Cervarix, a vaccine against human papillomavirus (HPV) types 16 and 18, showed that the vaccine continued to provide substantial protection against cervical precancers 4 years after vaccination. Cervarix provided almost complete protection in young women who had no evidence of exposure to HPV at the time of vaccination. The vaccine provided less protection for the total vaccinated cohort and was less effective with increasing age at vaccination. These findings reflect the vaccine’s lack of effectiveness against infections acquired before vaccination. The vaccine also partially protected women against four types of HPV that are not targeted by the vaccine. (Although HPV-16 and -18 cause about 70 percent of cervical cancers worldwide, as many as 15 HPV types can cause cancer.) These results from the PATRICIA trial (Papilloma Trial against Cancer in Young Adults) were published online November 9 in Lancet Oncology in two separate papers, available here and here. The PATRICIA trial enrolled 18,644 young women between the ages of 15 and 25 from 14 countries. The participants were randomly assigned to receive either three doses of Cervarix or three doses of a hepatitis A vaccine as a control. Results from the interim analysis, published in July 2009, showed that the vaccine greatly reduced the risk of grade 2 cervical intraepithelial neoplasias and higher (CIN2+). The new analysis shows that, 4 years after vaccination, Cervarix provided complete protection against grade 3 cervical intraepithelial neoplasias or higher (CIN3+) associated with HPV-16 and [...]

Oral Cancer Foundation News Team - A2011-11-29T18:55:35-07:00November, 2011|Oral Cancer News|

Data Published in the Lancet Oncology Support High Efficacy Previously Demonstrated By Cervarix

Source: Therapeutics Daily Author: Staff LONDON, Nov. 9, 2011-An analysis published today in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix®, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against human papillomavirus (HPV) types 16 and 18. CIN3+ is the immediate step before invasive cervical cancer and data showing protection against this type of lesion are considered the most stringent evidence of potential cervical cancer prevention.1 Results from the largest efficacy trial of a cervical cancer vaccine to date (PATRICIA), show that Cervarix provided 93%† efficacy against CIN3+ irrespective of the HPV type associated with the CIN3+ lesion.1This pre-defined, exploratory analysis was conducted in women with no evidence of past or current HPV infection.‡ These women are thought to be representative of young girls prior to the onset of sexual activity – the primary target population for organised vaccination programmes. These findings have been incorporated into the European label for Cervarix, updated by the European Commission in September 2011. Additional data from the same end-of-study analysis have been published in a separate article in TheLancet Oncology. These data demonstrate that Cervarix provided 82%* efficacy against CIN3+, associated with a composite of 12 cancer-causing HPV types not included in the vaccine, in the same population as the analysis discussed above.2 This analysis excluded cases co-infected with HPV 16 and/or 18 and is therefore a conservative estimate of cross-protective efficacy. Non-vaccine HPV types, including the 12 studied in this analysis, together account for approximately 30% of cervical cancers globally.3 The authors [...]

Charlotte Parker2011-11-16T12:04:02-07:00November, 2011|Oral Cancer News|

HPV Vaccination Could Reduce the Number of Screening Procedures

The National Journal By Sophie Quinton Widespread vaccination against cervical cancer could reduce the need for burdensome screenings, U.S. and Finnish researchers said on Tuesday. A study published in the journal Lancet Oncology show that GlaxoSmithKline’s Cervarix vaccine, which protects against two strains of human papillomavirus, or HPV, was more than 93 percent effective in preventing precancerous lesions in women who had never been infected and completely protected young women from the strains of virus targeted by the vaccine. The vaccine also reduced cancer risk for women who had already been infected by HPV, but was far less effective. A second study found that Cervarix can protect against rarer strains of HPV that also cause cancer. Neither study looked at Gardisil, the other licensed HPV vaccine, which protects against four strains of HPV—including the two targeted by Cervarix. The efficacy of vaccination adds fuel to two debates: how often women need to undergo cervical cancer screenings, and how important it is to reach girls—and boys—with HPV vaccinations before they become sexually active. The U.S. Preventive Services Task Force, American Cancer Society, and other clinical groups have agreed that the pap smear—the screening for cervical cancer—does not need to be done every year for most women, and suggest that screenings begin at age 21. For vaccinated women, the need for screening might be further reduced. “Provided that organised vaccination programs achieve high coverage in early adolescents before sexual debut, HPV vaccination has the potential to substantially reduce the incidence of cervical [...]

Charlotte Parker2011-11-08T20:47:32-07:00November, 2011|Oral Cancer News|

CDC Committee Recommends Boys Receive HPV Vaccine

Source: CNN.com A federal government advisory committee voted Tuesday to recommend that boys and young men, from ages 11 to 21, be vaccinated against the human papilloma virus, commonly referred to as HPV. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices says the vaccine series can be started as early as age 9. Twelve members of the committee voted in favor of a recommendation that 11- and 12-year-old boys be vaccinated; one member abstained. A separate vote involving males age 13 to 21 was split. Eight voted for it; five voted against, and one abstained. The same recommendation said males age 22 through 26 may be vaccinated. HPV is the No. 1 sexually transmitted disease in the United States. At least 50% of sexually active people will get it at some point in their lives. Study: Males should get HPV vaccine too The HPV votes took place as part of the advisory committee's meeting in Atlanta, Georgia. The HPV vaccine is already recommended for females between the ages of 9 and 26 to reduce the risk of cervical cancer. The CDC recommends girls get the vaccine at age 11 or 12. The FDA approved the first HPV vaccine, Gardasil, back in 2006. The second vaccine, Cervarix, was approved in 2009. The vaccine is given in three doses. Gardasil also protects against most genital warts and has been shown to protect against anal, vaginal and vulvar cancers, all of which are associated with HPV, according to the [...]

Oral Cancer Foundation News Team - A2011-10-25T13:47:57-07:00October, 2011|Oral Cancer News|

Oral cancers on rise due to HPV

Source: gargoyle.flagler.edu Author: staff Many Flagler College students are reconsidering human papillomavirus (HPV) vaccines due to the growing number of head and neck cancers in the United States caused by the HPV virus. According to a new study in the Journal of Clinical Oncology, the number of cases of oropharyngeal cancer, which are cancers of the tonsils, throat and base of the tongue, have been rising since the mid-1980s. “I got all three shots because I was influenced by my doctor and my mom because it seemed like a good way to protect myself,” said student Courtney Fusilier. “I think people should get it if they don’t want to die from those types of cancer.” The causes of oral cancers function within two categories: cancer caused by tobacco and alcohol and cancer caused by the sexually transmitted virus, HPV, researchers said. Researchers now believe that 70 percent of oropharyngeal cancers are caused by HPV. “The HPV status of a patient’s tumor is the single greatest determinant of whether a person lives or dies after a diagnosis of local-regionally advanced oropharynx cancer,” Gillison said. According to Gillison, about 95 percent of the HPV-positive oropharynx cancers were caused by HPV16. This strain is specifically targeted by Gardasil and Cervarix, which are two vaccines on the market to prevent cervical cancer. Communication major Adair Findley believes the HPV vaccines should be taken for a good piece of mind. “HPV is the most common sexually transmitted infection so I think it is important to [...]

Oral Cancer Foundation News Team - A2011-10-15T05:19:56-07:00October, 2011|Oral Cancer News|

New HPV Study Proves Vaccine’s Effectiveness

Source: Cancer.gov A flurry of new research findings on a vaccine that prevents persistent infections by cancer-causing types of the human papillomavirus (HPV) has confirmed the vaccine's efficacy and opened new avenues for research. The results, published in three separate reports, suggest that the vaccine could be simpler to administer and more affordable than researchers had previously thought—and that the vaccine may also have unexpected benefits. All three studies originate from an ongoing clinical trial of Cervarix in Costa Rica. The new findings could help inform efforts to develop vaccination programs to prevent cervical cancer in countries around the world, the researchers said. "The results from our trial and from other trials are extremely promising for this vaccine," said Dr. Allan Hildesheim of NCI's Division of Cancer Epidemiology and Genetics (DCEG), a leader of the trial. "And they suggest that the impact of the vaccine may go beyond cervical disease." HPV infections can lead to cancers of the anus, vagina, vulva, penis, and some oropharyngeal cancers, in addition to cervical cancer. Cervarix is one of two HPV vaccines currently approved by the Food and Drug Administration to prevent these infections; the other is Gardasil. One of the studies found that fewer than the prescribed three doses of Cervarix may offer the same protection as the full course. If confirmed, this could make vaccination easier to administer and more affordable, factors that are especially important in developing countries that have high rates of cervical cancer. A second study from the Costa [...]

Oral Cancer Foundation News Team - A2011-09-27T11:19:48-07:00September, 2011|Oral Cancer News|

HPV Vaccine and Premarital-Sex Controversy

Source: The News Tribune Some perspective is needed on the controversy over the Human Papillomavirus (HPV) vaccine that arose after a recent Republican presidential debate. The best way to do that is to take sex out of the equation. Instead of preventing a sexually transmitted disease that can lead to cervical cancer in women and oral cancer in men, let’s say the HPV vaccine guarded against a fictional virus that caused breast cancer and prostate cancer. Wouldn’t most parents jump at the chance to decrease the chances of their children contracting those potentially deadly cancers? Only the most hard-core anti-vaccine holdout would say no. Which gets us back to the sex part of the HPV equation and why some otherwise rational people don’t think children should be inoculated against it. They oppose the HPV vaccine – Cervarix or Gardasil – because they fear that removing one of the consequences of premarital sex would encourage it. It’s a weak argument. The fear of STDs and pregnancy hasn’t put much of a damper on teens having sex, so it’s hard to see why the chance of developing cancer several years down the road would slow them down. They also know that smoking can cause lung cancer, but many still do it. Sometimes parents have to do things to protect kids from themselves – and teens from their hormones. Most young people will not wait until marriage to have sexual relations; parents who think not getting their children vaccinated against HPV will deter [...]

Oral Cancer Foundation News Team - A2011-09-27T10:32:53-07:00September, 2011|Oral Cancer News|